Month: March 2023

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

Interim Analysis of Registration-Enabling Phase 3 Fibromyalgia Trial of TNX-102 SL Expected Second Quarter 2023; Topline Data Expected Fourth Quarter 2023 Potentially Pivotal Phase 2 Trials of TNX-1900 in Chronic Migraine and TNX-601 ER in Depression Scheduled for Interim Analyses in Fourth Quarter 2023 Potentially Pivotal Phase 2 Fibromyalgia-Type Long COVID Study Enrolling Cash and Cash Equivalents Totaled Approximately $120.2 Million at December 31, 2022 CHATHAM, N.J., March 13, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an overview of recent operational highlights. “Our clinical activity is at a high point in the Company’s...

Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

Amyotrophic lateral sclerosis (ALS): Significant survival benefits demonstrated across two ALS clinical trials, along with clinical improvements as early as six monthsCNM-Au8® associated with 74% lower risk of ALS clinical worsening events at six months supporting a survival benefit in the HEALEY ALS Platform Trial CNM-Au8 significantly preserved physical function (ALSFRS-R) from randomization to 48 weeks in the RESCUE-ALS Trial OLE follow-upMultiple sclerosis (MS): Significant improvements in MS clinical outcomes including the visual system and global neurological function on top of immunomodulatory background standard-of-care in the VISIONARY-MS trial; significant paraclinical MRI and visual evoked potential (VEP) improvements reinforce clinical benefits:CNM-Au8 significantly improved information signaling from the eye to the...

Alamos Gold Announces Appointment of Greg Fisher as Chief Financial Officer

Written by Customer Service on March 13, 2023. Posted in Public Companies.

TORONTO, March 13, 2023 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) today announced that Greg Fisher, Senior Vice President of Finance has been promoted to Chief Financial Officer effective May 1, 2023. Greg will succeed Jamie Porter who will be leaving Alamos to pursue another opportunity in the mining industry. Jamie will continue in his current capacity and help support the transition until April 28, 2023. Greg Fisher has more than 20 years of progressive experience in the mining sector, including 13 years at Alamos Gold. Greg joined Alamos in 2010 and was appointed Vice President of Finance in 2011 and Senior Vice President of Finance in 2021. During this time, he has led the finance team and has had responsibility for regulatory financial reporting, treasury management, budgeting and...

Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

• Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share1 • Total revenue for Q4 2022 was $60.7 million, compared to $42.3 million in Q4 2021 • FY 2022 net income was $2.76 per basic and $2.73 per diluted share and adjusted non-GAAP net income was $7.87 per basic and $7.79 per diluted share1 • FY 2022 revenue was $316.6 million compared to $171.5 million in FY 2021 • FY 2022 net sales of PEMFEXY® totaled $67.5 million, and were $12.1 million in Q4 2022, representing a 6% U.S. market share in community oncology at the end of Q4 2022; already captured a 10% share through February 2023; anticipate exiting Q1 2023 with 12% share2 • BENDEKA®3 and BELRAPZO®4 – both ready-to-dilute (“RTD”) products — combined maintained approximately 88% share of...

Quick Delivery Commerce Market is Projected to Surpass USD 2335.60 Billion by 2030 at a CAGR of 18.90% from 2023 to 2030; Growing Demand for Fast and Convenient Delivery of Goods and Services to Propel Market Growth

Written by Customer Service on March 13, 2023. Posted in Mergers And Acquisitions.

SkyQuest, a leading market research firm, has just published an in-depth report on the quick delivery commerce market, providing valuable insights and analysis on this rapidly growing industry. This report is an essential resource for companies and individuals seeking to invest in the market, offering reliable information on growth projections, segment breakdowns, emerging trends, and lucrative business prospects. Moreover, the report highlights several emerging trends likely to shape the market’s future, including drone technology, the rise of subscription-based services, and the increasing adoption of contactless delivery options. Westford, USA, March 13, 2023 (GLOBE NEWSWIRE) — The Asia Pacific region has become a significant player in the quick delivery commerce market. Thanks to the widespread availability of smartphones...

Calibre Scientific Acquires AlphaScience, a German Provider of Diagnostics Products, to Expand Product Portfolio and Customer Reach in the Dach Region

Written by Customer Service on March 13, 2023. Posted in Mergers And Acquisitions.

LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) — Calibre Scientific is pleased to announce the acquisition of AlphaScience GmbH (“AlphaScience” or the “Company”), a diagnostics provider with headquarters in Frankfurt, Germany. AlphaScience will be integrated with BIOZOL Diagnostica GmbH, a subsidiary of Calibre Scientific, enhancing its sales capabilities and product range for customers in the DACH region. AlphaScience is a provider of consumables and equipment for the commercial lab, clinical lab, academic, research, and hospital industries. The Company’s diagnostics product portfolio covers a wide variety of end market applications, including autoimmune, allergy, clinical chemistry, infectious disease, general lab supplies, molecular diagnostics, and reagents, among others. With this acquisition, BIOZOL further enhances its leading...

INVL Baltic Sea Growth Fund-backed Eglės Sanatorija acquires a rehabilitation services company in Vilnius

Written by Customer Service on March 13, 2023. Posted in Public Companies.

Eglės Sanatorija, a portfolio company of the INVL Baltic Sea Growth Fund, the leading private equity fund in the Baltic region, has acquired Reabilita.lt, a provider of rehabilitation services in the Lithuanian capital Vilnius. Until now Eglės Sanatorija, which is the largest sanatorium treatment and medical rehabilitation centre in the Baltics, served customers only in Druskininkai and Birštonas. “This is Eglės Sanatorija’s first day centre, which will offer procedures long valued by the medical spa’s customers for their important effects on the health-recovery process. We want to be closer to our customers so that they can focus more on recovering and improving their health and can continue treatment they began in Birštonas or Druskininkai in Vilnius and vice versa,” says Artūras Salda, the Director General at Eglės Sanatorija. Nerijus...

DISRUPTIVE CAPITAL ACQUISITION COMPANY LIMITED (“DCAC” or the “Company”) Option for DCAC to acquire the entire issued share capital of Global InterConnection Group SA

Written by Customer Service on March 13, 2023. Posted in Mergers And Acquisitions.

DISRUPTIVE CAPITAL ACQUISITION COMPANY LIMITED (“DCAC” or the “Company”) Option for DCAC to acquire the entire issued share capital of Global InterConnection Group SA in respect ofDCAC Shareholders (ISIN Code GG00BMB5XZ39) and DCAC Public Warrant Holders (ISIN Code GG00BMB5XY22) 13 March 2023 THIS PRESS RELEASE CONTAINS INFORMATION THAT QUALIFIES OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EU MARKET ABUSE REGULATION. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF APPLICABLE SECURITIES LAWS The proposed...

Shell Plc Fourth Quarter 2022 Euro and Gbp Equivalent Dividend Payments

Written by Customer Service on March 13, 2023. Posted in Dividend Reports And Estimates.

SHELL PLC FOURTH QUARTER 2022 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS March 13, 2023 The Board of Shell plc (the “Company”) today announced the pounds sterling and euro equivalent dividend payments in respect of the fourth quarter 2022 interim dividend, which was announced on February 2, 2023 at US$0.2875 per ordinary share. Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by March 3, 2023 will be entitled to a dividend of US$0.2875, €0.2716 or 24.11p per ordinary share, respectively. Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros at the euro rate per ordinary share...

Ageas initiated exclusive negotiations for the disposal of its French activities

Written by Customer Service on March 13, 2023. Posted in Public Companies.

Ageas initiated exclusive negotiations for the disposal of its French activities Ageas has entered into exclusive negotiations with La Mutuelle Epargne Retraite Prévoyance Carac (“Carac”) regarding the sale of its French life insurance, savings and pension business subject to certain conditions precedent. Ageas French Life and Pension activities consist of Ageas France, Ageas Retraite, Ageas Patrimoine and Sicavonline. As of end 2022, the consolidated perimeter represented an Unrestricted Tier 1 of EUR 161 million*, a Solvency II ratio of 216%**, IFRS technical provisions of EUR 3.9 billion, and an IFRS Net Profit of EUR 6.1 million. Carac is a mutual operating in the domain of savings, protection and pension business in France. The proposed disposal aligns with Ageas’s strategy to streamline its European portfolio and to concentrate on...

Month: March 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals